First Type 1 Diabetes Patient Enrolled in Rise Therapeutics’ Latest Clinical Trial
Rise Therapeutics, a clinical-stage biotechnology company developing novel oral immunotherapeutic medicines, announced it has enrolled its first patient in its R-5280 placebo-controlled, blinded, Phase 1b type 1 diabetes clinical trial.
